Sunday 18 October 2026
Export VTVT’s income statement to Excel — free account
vTv Therapeutics Inc.
VTVT Healthcare Biotechnology
In the quarter to June 2026, revenue grew 409,222.2%, EPS fell 14.1% and free cash flow fell 124.6%, each against the same quarter a year earlier.
26.54
1.05
−3.81%
Follow VTVT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | — |
P/S ratio |
— | — | 13.00 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | 53.76 | — | |
P/B ratio |
— | — | 5.47 | — | |
Price to Tangible BV |
— | — | 5.47 | — | |
EV/Sales |
— | — | 10.44 | — | |
EV/EBITDA |
— | — | 0.00 | — | |
EV/Operating CF |
— | — | (37.97) | — | |
EV/FCF |
— | — | (37.65) | — | |
Quick Ratio |
9.69 | 13.39 | 14.25 | 12.35 | |
Current Ratio |
9.79 | 13.54 | 14.36 | 12.48 | |
Net Debt/EBITDA |
9.21 | 11.28 | (4.22) | 6.22 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.58 | 0.00 | |
Operating CF/Net income |
0.60 | 1.30 | 0.38 | 0.88 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(2,139.80) | (7,885.00) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 24.37% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 12.48% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 3.77% | 0.00% | |
Graham Net Nets |
— | — | 0.18 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (1.61%) | — | |
Free Cash Flow Yield |
— | — | (2.13%) | — | |
Revenue per Share |
0.00 | 0.00 | 2.97 | 0.00 | |
Operating CF per Share |
(0.65) | (1.10) | 0.74 | (0.92) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.65) | (1.10) | 0.74 | (0.92) | |
Cash per Share |
12.23 | 10.56 | 7.90 | 6.98 | |
Shareholders Equity per Share |
8.76 | 7.65 | 7.25 | 6.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.76 | 7.65 | 7.25 | 6.34 | |
Free Cash Flow |
(5.22) | (9.25) | 9.15 | (11.44) | |
Working Capital |
89.29 | 83.25 | 91.93 | 80.57 | |
Net Current Asset Value |
70.51 | 64.43 | 89.95 | 78.63 | |
EV/EBIT |
— | — | 0.00 | — | |
Capex to Sales |
— | — | 0.00 | — | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Payables |
8.01 | 5.79 | 5.51 | 6.10 | |
Average Assets |
71.33 | 64.08 | 65.42 | 57.02 | |
Average Common Equity |
44.23 | 39.37 | 49.43 | 40.52 |
Columns are period end dates